Boryung Pharmaceutical Co., Ltd
Clinical trials sponsored by Boryung Pharmaceutical Co., Ltd, explained in plain language.
A South Korean pharmaceutical company producing prescription drugs and consumer health products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Diabetes drug switch: could a new combo improve blood sugar? Results expected Oct 2026 (estimated)
- New chemo formula may reduce Alcohol-Like reactions in breast cancer patients Results expected Oct 2026 (estimated)
- New pill aims to tame high blood pressure in 8 weeks Results expected Feb 2027 (estimated)
- Colon cancer study aims to improve treatment for older patients Results expected Feb 2027 (estimated)
- New dosing strategy for schizophrenia drug aims to cut side effects Results expected May 2027 (estimated)
-
New combo pill targets two heart risks at once
Disease control CompletedThis Phase 3 trial tested whether taking two experimental drugs, BR1018B and BR1018C, together can safely lower both blood pressure and LDL cholesterol. The study involved 156 adults with essential hypertension and primary hypercholesterolemia. Participants were randomly assigned…
Phase 3 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug candidate BR101801 tested in advanced blood cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …
Phase 1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:53 UTC
-
Real-World check: combo cholesterol pill works in daily practice
Disease control CompletedThis completed study observed 1,839 adults with primary high cholesterol who were prescribed a fixed-dose combination of atorvastatin and ezetimibe for 24 weeks. Researchers collected data on how well the pill lowered LDL cholesterol and tracked any safety issues. The goal was to…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:21 UTC
-
Real-World study reveals how anesthesia reversal drug is actually used
Knowledge-focused CompletedThis study observed over 6,400 adults undergoing elective surgery to see how doctors prescribe sugammadex, a drug that reverses muscle paralysis from anesthesia. Researchers collected data from routine care, without extra tests or treatments. The goal was to understand prescripti…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Real-World chemotherapy patterns in advanced pancreatic cancer revealed
Knowledge-focused CompletedThis study observed 799 adults with advanced or metastatic pancreatic cancer in Korea to see which chemotherapy treatments doctors actually use and why. Researchers tracked treatment choices, survival times, and quality of life. The goal was to understand real-world practice, not…
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:16 UTC
-
Healthy volunteers help test new combo pill for heart health
Knowledge-focused CompletedThis early-stage study tested how the body processes three experimental drugs (BR1018, BR1018A, and BR1018B) in 60 healthy adults. The goal was to measure drug levels and check safety, not to treat any condition. Results will guide future studies for high blood pressure and high …
Phase 1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:06 UTC